Skip to content

Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8

Reinforcing Effects of Brief Exposures to Nitrous Oxide

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000256
Enrollment
11
Registered
1999-09-21
Start date
1995-08-31
Completion date
1996-11-30
Last updated
2015-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid-Related Disorders, Substance-Related Disorders

Keywords

nitrous oxide, reinforcer, subjective effects, healthy volunteer

Brief summary

The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. Comparisons between nitrous oxide, opiates, and benzodiazepine antagonists will be made. To examine reinforcing effects of brief exposures to nitrous oxide in healthy volunteers.

Interventions

DRUG60% N2O
DRUG80% N2O

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
University of Chicago
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
22 Years to 34 Years
Healthy volunteers
Yes

Inclusion criteria

Please contact site for information.

Design outcomes

Primary

MeasureTime frameDescription
Choice of nitrous oxide vs placeboAfter 1.5 min of inhalation each of nitrous oxide then placeboSubjects underwent 4 sessions consisting of 2 sample tests (inhaling placebo and inhaling varying doses of N2O), then choosing which inhalant they wanted for a choice test. The subject & the technician administering the inhalant were blinded. During each intervention and each session, subjects underwent psychomotor testing.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026